Glycolipid entries from the LIPID MAPS Structure Database (LMSD).
Database | Last Updated |
---|---|
ChEBI | February 3, 2022 |
KEGG | February 3, 2022 |
LIPID MAPS Structure Database | February 3, 2022 |
LipidBank | February 3, 2022 |
PubChem | February 3, 2022 |
Main Class | Sub Class | LM ID | Common Name ▼ | LipidBank ID | KEGG ID | PubChem CID | ChEBI ID | Exact Mass | Formula |
---|---|---|---|---|---|---|---|---|---|
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II antigen(d18:1/20:0)
|
1428.870453
|
C70H128N2O27
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II antigen(d18:1/18:0)
|
1400.839153
|
C68H124N2O27
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II antigen(d18:1/16:0)
|
1372.807853
|
C66H120N2O27
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/26:1(17Z))
|
1876.080902
|
C90H161N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/26:0)
|
1878.096552
|
C90H163N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/24:1(15Z))
|
1848.049602
|
C88H157N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/24:0)
|
1850.065252
|
C88H159N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/22:0)
|
1822.033952
|
C86H155N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/20:0)
|
1794.002652
|
C84H151N3O37
|
|||||
Neutral glycosphingolipids
|
Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)
|
type II H antigen(d18:1/18:0)
|
1765.971352
|
C82H147N3O37
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01